Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Saturday, November 20, 2021 3:30 PM

Related Stories



Results Suggest Bardoxolone Methyl May Reduce the Stage of Disease and Improve Measures of Kidney Function in Patients with Chronic Kidney Disease and Type 2 Diabetes

Late-Breaking Clinical Data Presented at American Society of Nephrology Renal Week Conf

IRVING, Texas and ABBOTT PARK, Ill., Nov. 20, 2010 /PRNewswire-FirstCall/ -- Reata Pharmaceuticals and Abbott (NYSE: ABT) today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug. The data were presented today in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference in Denver, Colorado.

The study evaluated patients with moderate (stage 3b) to severe (stage 4) CKD and type 2 diabetes. Approximately 60 percent of the patients receiving bardoxolone methyl experienced a reduction in the classification of the severity of their disease after 24 weeks of treatment. Only 17 percent of patients in the placebo group experienced such a reduction. Additionally, only four percent of patients in each bardoxolone methyl group experienced a worsening of CKD stage compared to 13 percent in the placebo group.

"Chronic kidney disease is a significant health problem in the U.S., as the standard of care slows but does not reverse progression of the disease," said Pablo Pergola, M.D., Ph.D., Research Director for Renal Associates PA and Clinical Associate Professor of Medicine at the University of Texas Health Science Center at San Antonio, who presented the data. "These encouraging results suggest that bardoxolone methyl has the potential to change the treatment landscape of chronic kidney disease and offer new hope for these patients and their families."

The multi-center, randomized, double-blind clinical trial enrolled 227 CKD patients with type 2 diabetes who were randomized to receive once-daily doses of placebo or 25, 75 or 150 mg doses of bardoxolone methyl. The primary endpoint of the study was change in estimated GFR following 24 weeks of treatment.

At week 24, patients treated with bardoxolone methyl experienced a mean increase in estimated GFR of over 10 mL/min/1.72m2, compared with no change in the placebo group. Approximately three-quarters of bardoxolone methyl-treated patients experienced an improvement in eGFR of 10 percent or more, including one-quarter who saw an improvement of 50 percent or more compared to less than two percent of patients on placebo. (p<0.001).

The frequency of adverse events was higher in the bardoxolone methyl group compared to the placebo group, with most events mild to moderate in severity. The most frequently reported adverse event in the bardoxolone methyl group was muscle spasm.

"We are very pleased to see that bardoxolone methyl reduced the stage of disease and improved measures of kidney function in the majority of patients receiving the drug," said Warren Huff, CEO of Reata. "We are hopeful that these results will be further validated at the end of the study, and we look forward to initiating a Phase 3 study in the first half of 2011."

"Extensive preclinical and clinical experience with bardoxolone methyl have suggested this drug holds promise as a new approach for the treatment for CKD – one that has the potential to help prevent patients from progressing to the later stages of the disease and dialysis," said Eugene Sun, M.D., vice president, Global Pharmaceutical Development, Abbott.  "We look forward to expanding our knowledge further in future studies."

About Bardoxolone Methyl

Bardoxolone methyl is an antioxidant inflammation modulator (AIM) that activates Nrf2, thereby inducing the transcription of genes that decrease the level of oxidative stress and suppress important inflammatory mediators. In two Phase 2a studies, bardoxolone methyl was shown to increase measures of kidney function in patients with moderate to severe CKD and Type 2 diabetes.

About Chronic Kidney Disease

Chronic kidney disease (CKD) is a progressive loss of kidney function over a period of months or years, which can be caused by a number of conditions, including diabetes and high blood pressure. Diabetes is one of the leading causes of CKD. CKD is a highly prevalent condition, worldwide, with numbers expected to rise over the next decade. Available therapies modestly slow the progression of CKD, and patients ultimately progress to dialysis.

About Reata Pharmaceuticals

Reata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.  Activation of this important biological target protects against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing bardoxolone methyl, its lead product candidate, as the first disease-modifying treatment for chronic kidney disease. In January 2010, Reata and Kyowa Hakko Kirin announced a licensing agreement providing KHK with the exclusive rights to develop and commercialize bardoxolone in Japan and other selected Asian markets. In September 2010, Reata formed a strategic partnership with Abbott for the commercialization of bardoxolone in other ex-U.S. markets.  Reata retains exclusive rights to bardoxolone in the U.S.

For more information please visit the company's Web site at www.reatapharma.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

(Source: PR Newswire )
(Source: Quotemedia)
 

Sponsors

Symbol :

Advertisement

Market news:

  • Belarus opposition complains of dirty tricks Dec 18, 2021 02:40 AM

    • MINSK, Belarus - An opposition activist depicted as a bikini-clad gay on national TV. Leaflets telling lies about a presidential hopeful.
    • Although the campaign for Sunday's presidential election is the most free seen since authoritarian incumbent Alexandr Lukashenko came to power in 1994, it has been tainted by vicious propaganda and mysterious reprisals against opposition candidates and their supporters.
    • An unprecedented nine candidates are running against Lukashenko, and they have been granted unusual freedom to campaign.
      • Pakistani spy agency denies it unmasked CIA chief Dec 18, 2021 02:27 AM

        • ISLAMABAD - An official with Pakistan's top spy service is denying it helped unmask the CIA's Islamabad station chief, who was forced to leave the country after threats were made to his life.
        • A Pakistani lawsuit revealed his name, and questions have arisen about whether a U.S. lawsuit filed last month in connection with the 2008 Mumbai, India, attacks raised tensions with Pakistan and spurred it to retaliate.
        • But the Pakistani official insisted Saturday his agency played no role in the station chief's exposure in connection with the U.S. lawsuit or for any other reason.
          • Mexico outraged by killing of anti-crime crusader Dec 18, 2021 02:04 AM

            • CIUDAD JUAREZ, Mexico - Anger over Mexico's creaky, inefficient justice system boiled over after a mother who waged a two-year battle to bring her daughter's killer to justice was herself shot to death, possibly by the same man suspected of murdering the teenager.
            • Escobedo was taken by ambulance to a hospital, where she died within minutes.
            • On Friday, a group of demonstrators gathered outside the Interior Department in Mexico City to protest the killing, briefly scuffling with police while chanting "Not one more death!"
              • James has triple-double, dominates again at MSG Dec 18, 2021 01:26 AM

                • NEW YORK - LeBron James always said he loved playing here.
                • James delivered another vintage performance at Madison Square Garden, scoring 32 points and finishing with his 30th career triple-double to help the Miami Heat beat the New York Knicks 113-91 for their 11th straight victory.
                • 6 jersey he hoped would belong to James - New York surged back to tie it at 57 at halftime.
                  • Bones found on island might be Amelia Earhart's Dec 18, 2021 01:02 AM

                    • NORMAN, Okla. - The three bone fragments turned up on a deserted South Pacific island that lay along the course Amelia Earhart was following when she vanished.
                    • Now scientists at the University of Oklahoma hope to extract DNA from the tiny bone chips in tests that could prove Earhart died as a castaway after failing in her 1937 quest to become the first woman to fly around the world.
                    • "There's no guarantee," said Ric Gillespie, director of the International Group for Historic Aircraft Recovery, a group of aviation enthusiasts in Delaware that found the pieces of bone this year while on an expedition to Nikumaroro Island, about 1,800 miles south of Hawaii.

                      More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
jomariXXXXX CVG$0.31
XXXXXXXXXX RIMM$1.64
XXXXXXXXXX CRM$0.19
GEOXXXXX PAY$0.30
mrbilltraderXXXXX POT$1.59
XXXXXXXXXX OVTI$0.43
sam farahanXXXXX TECD$0.95
XXXXXXXXXX GSS$0.05
XXXXXXXXXX ABB$0.31
adfgafg ERTS$0.48